Allopurinol lowers risk of macular edema among diabetes patients Medha Baranwal16 Feb 2023 2:30 PM GMTUSA: A recent study published in Ocular Immunology and Inflammation has shown that allopurinol could reduce the risk of diabetic macular edema (DME)....
Zydus Lifesciences bags USFDA nod for Febuxostat Tablets to treat high uric acid Ruchika Sharma11 Jan 2023 6:17 AM GMTAhmedabad: Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) has received final approval from the United States Food and Drug...
Older patients with CKD who started allopurinol at higher risk of severe cutaneous reaction Dr. Shravani Dali11 Dec 2022 2:30 PM GMTOlder patients with CKD who started allopurinol at >100 mg/d versus <100 mg/d were twice as likely to visit a hospital with a severe cutaneous...
Use of Allopurinol Associated with Lower Risk of First Coronary Event among gout patients Dr. Kamal Kant Kohli16 Nov 2022 4:00 AM GMTSweden: Gout patients who take allopurinol have a lower risk of developing their first acute coronary syndrome (ACS), according to research published...
Allopurinol tied to less mortality compared to febuxostat among patients with CVD Aditi4 Nov 2022 2:30 PM GMTChina: A study published in the Frontiers in Pharmacology mentioning a comparison between Allopurinol and Febuxostat has concluded that allopurinol...
Allopurinol fails to improve CV outcomes in ischemic heart disease patients: ALL-HEART trial Dr.Niharika Harsha B12 Oct 2022 3:00 PM GMTA recent study found that allopurinol did not improve the primary outcomes in cardiovascular patients aged 60 years or older with ischemic heart...
Allopurinol not tied to mortality risk in patients with gout with CKD, study finds Medical Dialogues Editorial Team4 Feb 2022 3:30 AM GMTChina: A new study shows that neither the commencement of allopurinol, the achievement of the target serum urate (SU) level with allopurinol, nor the...
Allopurinol non-inferior to febuxostat for gout treatment: Study Medha Baranwal3 Dec 2021 3:30 AM GMTUSA: Allopurinol, when dosed appropriately as part of a treat-to-target strategy, is non-inferior to febuxostat for gout treatment, according to...
Allopurinol may increase CV risk, mortality in gout compared to benzbromarone: Study MD Editorial Team26 Nov 2021 3:30 AM GMTSouth Korea: Results from a large population-based cohort showed that allopurinol is related to an increased risk of all-cause mortality and composite...
Early allopurinol initiation in acute gout flare has no significant benefit: Study MD Editorial Team11 Oct 2021 3:30 AM GMTGout is among the most prevalent etiologies of chronic inflammatory arthritis in the United States. The evaluation and management of gout and...
Urate lowering agents don't slow progression of CKD in hyperuricemia, finds study MD Editorial Team7 Oct 2021 4:42 PM GMTHyperuricemia is very common in CKD patients because of reduced urinary excretion of uric acid. The role of uric acid in the development CKD and...
Febuxostat has similar CV safety as Allopurinol when used in Gout: Study Dr. Shravani Dali19 July 2021 4:00 AM GMTFebuxostat used for Gout did not substantially increase the risk of cardiovascular events or death when compared to the usage of Allopurinol,...
